← Harbin Pharmaceutical overview

Harbin Pharmaceutical vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Harbin Pharmaceutical Group Co Ltd (600664.CG)

Q3 2026
▲4

Harbin Pharma Surges on Drug List Inclusion, Strong Earnings, and Procurement Wins

  • National Essential Medicines List Inclusion Drives Demand 118 product specifications, including six new varieties, were added to China's 2026 National Essential Medicines List. This boosts sales visibility and demand for Harbin Pharmaceutical's drugs, pushing the stock up as investors expect higher volumes and revenue.

    This regulatory catalyst directly increases demand for the company's products and was a key driver of the stock's rally.

  • Strong First-Half Profit Growth Confirmed Harbin Pharmaceutical reported interim net profit of 410 million yuan, up 57.99% year on year, with improved gross margin and return on equity. The profit surge confirms operational strength, attracting investors and supporting the share price.

    Earnings growth is a fundamental driver that validates the stock's upward momentum and boosts investor confidence.

  • Centralized Procurement Wins to Lift Sales Harbin Pharmaceutical's products were proposed for selection in China's 12th round of national centralized drug procurement. Winning bids typically guarantee large-volume sales, which should increase revenue and support the stock price.

    Procurement wins provide a concrete demand boost and were highlighted as a positive signal for the company.

  • New API Approval Adds Product Portfolio Harbin Pharmaceutical's subsidiary received marketing approval for potassium sulfate API from the NMPA. While the financial impact is small, it expands the company's product offerings and reinforces its growth pipeline, contributing to positive sentiment.

    This regulatory approval is a new development that adds to the company's product range and supports its growth narrative.

August 2026
▲4

Harbin Pharma Surges on Drug List Inclusion, Strong Earnings, and Procurement Wins

  • National Essential Medicines List Inclusion Drives Demand 118 product specifications, including six new varieties, were added to China's 2026 National Essential Medicines List. This boosts sales visibility and demand for Harbin Pharmaceutical's drugs, pushing the stock up as investors expect higher volumes and revenue.

    This regulatory catalyst directly increases demand for the company's products and was a key driver of the stock's rally.

  • Strong First-Half Profit Growth Confirmed Harbin Pharmaceutical reported interim net profit of 410 million yuan, up 57.99% year on year, with improved gross margin and return on equity. The profit surge confirms operational strength, attracting investors and supporting the share price.

    Earnings growth is a fundamental driver that validates the stock's upward momentum and boosts investor confidence.

  • Centralized Procurement Wins to Lift Sales Harbin Pharmaceutical's products were proposed for selection in China's 12th round of national centralized drug procurement. Winning bids typically guarantee large-volume sales, which should increase revenue and support the stock price.

    Procurement wins provide a concrete demand boost and were highlighted as a positive signal for the company.

  • New API Approval Adds Product Portfolio Harbin Pharmaceutical's subsidiary received marketing approval for potassium sulfate API from the NMPA. While the financial impact is small, it expands the company's product offerings and reinforces its growth pipeline, contributing to positive sentiment.

    This regulatory approval is a new development that adds to the company's product range and supports its growth narrative.

Latest
▲4

Harbin Pharma Surges on Drug List Inclusion, Strong Earnings, and Procurement Wins

  • National Essential Medicines List Inclusion Drives Demand 118 product specifications, including six new varieties, were added to China's 2026 National Essential Medicines List. This boosts sales visibility and demand for Harbin Pharmaceutical's drugs, pushing the stock up as investors expect higher volumes and revenue.

    This regulatory catalyst directly increases demand for the company's products and was a key driver of the stock's rally.

  • Strong First-Half Profit Growth Confirmed Harbin Pharmaceutical reported interim net profit of 410 million yuan, up 57.99% year on year, with improved gross margin and return on equity. The profit surge confirms operational strength, attracting investors and supporting the share price.

    Earnings growth is a fundamental driver that validates the stock's upward momentum and boosts investor confidence.

  • Centralized Procurement Wins to Lift Sales Harbin Pharmaceutical's products were proposed for selection in China's 12th round of national centralized drug procurement. Winning bids typically guarantee large-volume sales, which should increase revenue and support the stock price.

    Procurement wins provide a concrete demand boost and were highlighted as a positive signal for the company.

  • New API Approval Adds Product Portfolio Harbin Pharmaceutical's subsidiary received marketing approval for potassium sulfate API from the NMPA. While the financial impact is small, it expands the company's product offerings and reinforces its growth pipeline, contributing to positive sentiment.

    This regulatory approval is a new development that adds to the company's product range and supports its growth narrative.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.